TY - JOUR
T1 - Core domain set for studies of acute calcium pyrophosphate crystal arthritis
T2 - OMERACT delphi survey to establish consensus
AU - Zhang, Yiling
AU - Tedeschi, Sara K.
AU - Abhishek, Abhishek
AU - Hensey, Owen
AU - Grossberg, David
AU - Cai, Ken
AU - Shea, Beverley
AU - Singh, Jasvinder A.
AU - Christensen, Robin
AU - Serban, Teodora
AU - Cipolletta, Edoardo
AU - Parperis, Konstantinos
AU - Diaz-Torne, Cesar
AU - McCarthy, Geraldine M.
AU - Becce, Fabio
AU - Gheita, Tamer A.
AU - Sirotti, Silvia
AU - Christiansen, Sara Nysom
AU - Coronel, Luis
AU - Stamp, Lisa K.
AU - Abdel-Fattah, Yousra H.
AU - Pascart, Tristan
AU - Filippou, Georgios
AU - Hong, Lih En
AU - FitzGerald, John
AU - Dalbeth, Nicola
PY - 2025/6
Y1 - 2025/6
N2 - Objective: To identify potential domains for the Outcome Measures in Rheumatology (OMERACT) core domain set for studies of an individual flare of acute calcium pyrophosphate (CPP) crystal arthritis. Methods: Patient research partners (PRPs) and other participants (mainly clinicians and researchers) completed three rounds of survey using Delphi methodology. Consensus was defined as ≥ 70 % of both PRP and other participants groups rated the domain as a ‘critically important domain to include’. In a subsequent ranking exercise, all participants were asked to rank and comment on up to 10 domains to include as core domains. Results: Fourteen domains reached consensus as critically important in the Delphi survey. In the Pathophysiological Manifestations area, the domains were joint pain, joint tenderness, joint swelling, joint inflammation on imaging tests and duration of acute CPP crystal arthritis flare. In the Life Impact area, the domains were overall function, ability to complete daily tasks, ability to work, health related quality of life, patient global assessment response to treatment, patient and physician global assessments of disease activity, and patient satisfaction with treatment. In the Societal/Resource Use area, use of rescue medications reached consensus. In the ranking exercise, joint pain, joint tenderness, joint swelling, overall function and ability to complete daily tasks ranked highest. Conclusion: Joint pain, joint swelling, joint tenderness, duration of acute CPP crystal arthritis flare, overall function, ability to complete daily tasks, and patient global assessment of disease activity received the strongest support to be included in the OMERACT core domain set for studies of acute CPP crystal arthritis.
AB - Objective: To identify potential domains for the Outcome Measures in Rheumatology (OMERACT) core domain set for studies of an individual flare of acute calcium pyrophosphate (CPP) crystal arthritis. Methods: Patient research partners (PRPs) and other participants (mainly clinicians and researchers) completed three rounds of survey using Delphi methodology. Consensus was defined as ≥ 70 % of both PRP and other participants groups rated the domain as a ‘critically important domain to include’. In a subsequent ranking exercise, all participants were asked to rank and comment on up to 10 domains to include as core domains. Results: Fourteen domains reached consensus as critically important in the Delphi survey. In the Pathophysiological Manifestations area, the domains were joint pain, joint tenderness, joint swelling, joint inflammation on imaging tests and duration of acute CPP crystal arthritis flare. In the Life Impact area, the domains were overall function, ability to complete daily tasks, ability to work, health related quality of life, patient global assessment response to treatment, patient and physician global assessments of disease activity, and patient satisfaction with treatment. In the Societal/Resource Use area, use of rescue medications reached consensus. In the ranking exercise, joint pain, joint tenderness, joint swelling, overall function and ability to complete daily tasks ranked highest. Conclusion: Joint pain, joint swelling, joint tenderness, duration of acute CPP crystal arthritis flare, overall function, ability to complete daily tasks, and patient global assessment of disease activity received the strongest support to be included in the OMERACT core domain set for studies of acute CPP crystal arthritis.
KW - Acute calcium pyrophosphate crystal arthritis
KW - Calcium pyrophosphate deposition disease
KW - Core domain set
KW - Delphi
KW - Domain
KW - Omeract
U2 - 10.1016/j.semarthrit.2025.152670
DO - 10.1016/j.semarthrit.2025.152670
M3 - Journal article
C2 - 40037058
AN - SCOPUS:85219007536
SN - 0049-0172
VL - 72
JO - Seminars in Arthritis and Rheumatism
JF - Seminars in Arthritis and Rheumatism
M1 - 152670
ER -